Alector, Inc. (ALEC)
Largest Insider Buys in Sector
ALEC Stock Price History Chart
ALEC Stock Performance
About Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that …
Insider Activity of Alector, Inc.
Over the last 12 months, insiders at Alector, Inc. have bought $0 and sold $1.4M worth of Alector, Inc. stock.
On average, over the past 5 years, insiders at Alector, Inc. have bought $1M and sold $46.15M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 40,000 shares for transaction amount of $1M was made by Wehner David M. (director) on 2020‑02‑03.
List of Insider Buy and Sell Transactions, Alector, Inc.
| 2024-12-02 | Sale | Chief Executive Officer | 52,172 0.0534% | $2.52 | $131,442 | -14.74% | ||
| 2024-12-02 | Sale | President and Head of R&D | 26,500 0.0271% | $2.52 | $66,764 | -14.74% | ||
| 2024-12-02 | Sale | Chief Medical Officer | 14,892 0.0152% | $2.52 | $37,519 | -14.74% | ||
| 2024-12-02 | Sale | Chief Financial Officer | 16,489 0.0169% | $2.52 | $41,542 | -14.74% | ||
| 2024-09-03 | Sale | Chief Executive Officer | 26,499 0.0282% | $4.88 | $129,387 | -1.59% | ||
| 2024-09-03 | Sale | President and Head of R&D | 13,926 0.0148% | $4.88 | $67,981 | -1.59% | ||
| 2024-09-03 | Sale | Chief Medical Officer | 8,478 0.009% | $4.88 | $41,385 | -1.59% | ||
| 2024-09-03 | Sale | Chief Financial Officer | 7,297 0.0078% | $4.88 | $35,620 | -1.59% | ||
| 2024-08-22 | Sale | director | 44,250 0.0463% | $5.16 | $228,388 | -4.34% | ||
| 2024-08-12 | Sale | director | 5,000 0.0051% | $5.06 | $25,309 | -3.72% | ||
| 2024-08-12 | Sale | director | 10,500 0.0108% | $5.06 | $53,179 | -3.72% | ||
| 2024-06-03 | Sale | Chief Executive Officer | 25,135 0.0249% | $4.80 | $120,618 | -2.77% | ||
| 2024-06-03 | Sale | President and Head of R&D | 13,206 0.0131% | $4.80 | $63,373 | -2.77% | ||
| 2024-06-03 | Sale | Chief Medical Officer | 8,040 0.008% | $4.80 | $38,582 | -2.77% | ||
| 2024-06-03 | Sale | Chief Financial Officer | 6,920 0.0068% | $4.80 | $33,208 | -2.77% | ||
| 2024-03-04 | Sale | Chief Executive Officer | 18,837 0.0195% | $6.92 | $130,386 | -25.43% | ||
| 2024-03-04 | Sale | President and Head of R&D | 10,169 0.0105% | $6.92 | $70,387 | -25.43% | ||
| 2024-03-04 | Sale | Chief Medical Officer | 6,001 0.0062% | $6.92 | $41,554 | -25.43% | ||
| 2024-03-04 | Sale | Chief Financial Officer | 5,716 0.0059% | $6.92 | $39,562 | -25.43% | ||
| 2023-12-04 | Sale | Chief Executive Officer | 23,831 0.028% | $5.56 | $132,500 | -0.71% |
Insider Historical Profitability
| GORDON CARL L | 10434976 10.6553% | $1.86 | 1 | 0 | +10.01% | |
| ORBIMED ADVISORS LLC | 10 percent owner | 1906718 1.947% | $1.86 | 1 | 17 | +10.01% |
| Wehner David M. | director | 44621 0.0456% | $1.86 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Fidelity Investments | $86.46M | 14.9 | 14.36M | +13.8% | +$10.49M | 0.01 | |
| BlackRock | $51.07M | 8.8 | 8.48M | +5.14% | +$2.5M | <0.01 | |
| The Vanguard Group | $29.57M | 5.1 | 4.91M | +11.99% | +$3.17M | <0.01 | |
| Ecor1 Capital Llc | $24.42M | 4.21 | 4.06M | 0% | +$0 | 0.17 | |
| State Street | $23.57M | 4.06 | 3.92M | +25.59% | +$4.8M | <0.01 |